ArticleThe European journal of health economics : HEPAC : health economics in prevention and care2024

Cost-effectiveness analysis alongside the inter-B-NHL ritux 2010 trial: rituximab in children and adolescents with B cell non-Hodgkin's lymphoma.

Béranger Lueza et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.